Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions.

Katz et al. (2003) read every drug study they could find on people with intellectual disability. They looked at how researchers picked clients, measured behavior, and checked side effects.

The team wrote a narrative review. They listed the flaws and gave clear fixes for future trials.

Most trials were too small and too short. Many used open-label designs with no placebo or blind raters.

Few studies tracked real-world behaviors like self-injury or adaptive skills. Side-effect reports were spotty.

Soto et al. (2024) later showed the payoff of better methods. Their hospital added an emotional-development assessment and cut antipsychotic use in adults with IDD. This real-world test proves the 2003 fixes work.

Yamashiro et al. (2019) and Mahé et al. (2025) found adults with ASD plus ID still receive more psychotropics than peers. These surveys extend the 2003 warning that weak science keeps fueling high prescribing.

Anonymous (2023) scanned 70 rare-ID guidelines and found most lack rigorous methods. The same gaps L et al. flagged in drug trials still haunt guideline panels two decades later.

Before you sign off on a med increase, demand an RCT or at least blinded data. Ask the team to record baseline rates of problem behavior and daily living skills. These simple steps turn the 2003 paper into safer, leaner prescribing for your clients with ID.